HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: 29/6/1212    most recent 09031936.00117506v1 Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (16) Citing Articles via Google Scholar Google Scholar Articles by Leyten, E. M. S. Articles by Arend, S. M. Search for Related Content PubMed PubMed Citation Articles by Leyten, E. M. S. Articles by Arend, S. M.

Effect of tuberculin skin testing on a Mycobacterium tuberculosis-specific interferon- assay

¹ Depts of Infectious Diseases and ⁴ Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, ² Depts of Pulmonology and ³ Microbiology and Immunology, Diakonessenhuis Utrecht/Zeist, Utrecht, The Netherlands.

CORRESPONDENCE: S. M. Arend, Dept of Infectious Diseases, C5P, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands. Fax: 31 715266758. E-mail: S.M.Arend{at}LUMC.nl

Keywords: Diagnosis, immunoassays, interferon, Mycobacterium tuberculosis, skin test, tuberculosis

Received: September 6, 2006
Accepted December 20, 2006

	ABSTRACT

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION ACKNOWLEDGEMENTS REFERENCES

 
Recently, interferon- release assays (IGRA) for specific diagnosis of Mycobacterium tuberculosis infection have become available. In recent UK tuberculosis (TB) guidelines, it has been advised to screen for latent M. tuberculosis infection using the tuberculin skin test (TST), followed by IGRA if the TST is positive. Since TST can boost immune responses to tuberculin, the present authors evaluated whether TST administration affects the result of QuantiFERON®-TB Gold in-tube (QFT-GIT), a whole blood-based IGRA.

QFT-GIT was performed on the day of TST administration and the day of reading in 15 TST-negative subjects, 46 TST-positive subjects with recent or remote exposure to M. tuberculosis and five cured TB patients.

No systematic boosting of QFT-GIT responses from negative to positive was observed. Only in a few TST-positive persons did TST enhance pre-existing QFT-GIT responses.

Screening for latent Mycobacterium tuberculosis infection using tuberculin skin testing followed by interferon- release assays on the day of reading is a reliable approach, as the specificity of QuantiFERON®-TB Gold in-tube is not affected by prior tuberculin skin test administration.

During the past century, the tuberculin skin test (TST) was the only available diagnostic tool for detection of latent infection with Mycobacterium tuberculosis. The most important limitation of this test is that the specificity is impaired by cross-reactive immune responses to Mycobacterium bovis bacille Calmette–Guérin (BCG) and environmental mycobacteria. Recently, new in vitro immunodiagnostic assays have been developed that were specifically designed to overcome this problem. These assays measure interferon (IFN)- production in whole blood or production of peripheral blood mononuclear cells (PBMC) in response to antigens that are specific for M. tuberculosis and absent from BCG and most environmental mycobacteria. Herein, these assays will be referred to as IFN- release assays (IGRA). The two most frequently used antigens are early secreted antigen of 6 kDa (ESAT-6; Rv3875) and culture filtrate protein (CFP)-10 (Rv3874); T-cell responses to these antigens were found to be sensitive as well as specific for the detection of tuberculosis (TB) 1, 2. The QuantiFERON®-TB Gold (QFT-G) is a commercial IGRA based on an overnight culture of whole blood with peptides of ESAT-6 and CFP-10. The reported sensitivity for detection of active TB infection was 85–90%, with a specificity of 98% 3, 4. In a contact investigation in a Danish school, mainly among BCG unvaccinated individuals, a modified QFT assay using recombinant antigens of ESAT-6 and CFP-10, was significantly correlated with exposure to the index case and showed excellent agreement with the TST 5. Recently, a novel in-tube format of QFT-G (QFT-GIT) has been marketed, which, apart from peptides of ESAT-6 and CFP-10, contains an additional peptide of the M. tuberculosis-specific antigen TB7.7 (Rv 2654) 6.

Although the novel IGRAs are highly specific for M. tuberculosis, the TST still remains a valuable assay, as its positive predictive value for the risk of development of active TB has been well documented 7. Moreover, the documented beneficial effect of isoniazid (INH) prophylaxis for the reduction of secondary TB cases is based on studies using TST results as the indicator for latent TB infection 8–10. According to recently issued guidelines by the National Institute for Health and Clinical Excellence (NICE) in the UK, a two-step procedure using TST followed by an IGRA in case the TST is positive, is advocated as the method of choice to screen for latent M. tuberculosis infection.

From the two-step TST, it is known that an increase in tuberculin reaction can be observed, which is believed to result from immunological recall of pre-existing delayed-type hypersensitivity response to mycobacterial antigens 11. Tuberculin contains fragments of the M. tuberculosis-specific antigens that are also used in QFT-G(IT). It is therefore conceivable that TST administration could also boost in vitro immune responses to peptides of these antigens. This would be relevant if TST and IGRA are used sequentially, as suggested in the above-mentioned NICE guidelines for TB. Implementation of sequential use of TST and IGRA would be facilitated if it can be demonstrated that IGRA can be reliably performed on the day of TST reading. The present study aimed to evaluate the effect of TST administration on the result of a commercially available IGRA, QFT-GIT, on the day of reading of the TST.

	MATERIALS AND METHODS

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION ACKNOWLEDGEMENTS REFERENCES

 
Study setting and study subjects
Study subjects
Persons aged 18 yrs with a documented TST induration of 10 mm after known exposure to M. tuberculosis and TST negative (0 mm) individuals were eligible for the study. Study subjects were recruited with the aim of covering a wide spectrum of ages and intervals since exposure or last TST, in order to allow evaluation of TST effect in relation to the time elapsed since infection with M. tuberculosis. The minimum interval since the last TST was 6 months in order to avoid hyperresponsive TST reactions. Individuals with a known immune defect due to HIV infection or treatment with immunosuppressive drugs were excluded from participation.

Study setting
The study protocol (P04-183) was approved by the Institutional Review Board of the Leiden University Medical Center, Leiden, The Netherlands. Oral and written informed consent was obtained from all study subjects. Prior to the TST, 2 mL of blood was obtained for QFT-GIT. The following data were collected by questionnaire: 1) demographic data; 2) medical history; 3) BCG vaccination status; 4) exposure to smear-positive TB patients; 5) indication for previous TST; 6) date of previous TST; and 7) previous TST results. All participants underwent a TST for the purpose of this study (day 0). The TST was read 72 h later (day 3) and, at the same time, a second blood sample of 2 mL was obtained for QFT-GIT.

Tuberculin skin testing
The TST was performed by trained personnel following standard procedures. In brief, 0.1 mL (2 TU) of purified protein derivative (PPD, RT23; Statens Serum Institute, Copenhagen, Denmark) was injected intradermally into the dorsal side of the left forearm. Transverse induration at the TST site was measured after 72 h by experienced personnel.

Whole blood IGRA, QFT-GIT
Blood samples of 1 mL were collected in two special tubes for the QFT-GIT (Cellestis Ltd. Carnegie, Victoria, Australia): one coated with M. tuberculosis-specific peptides of ESAT-6, CFP-10 and TB7.7 (Rv2654, only peptide 4) and one without antigen as negative control. Within 8 h of blood sampling, tubes were incubated for 24 h at 37°C, followed by centrifugation and cold storage until testing as specified by the manufacturer. The concentration of IFN- in plasma was measured using the commercial QFT-GIT ELISA. The test result was determined as either negative or positive (cut-off at 0.35 IU·mL^–1), using the software of the manufacturer (qualitative test result), and as the IFN- concentration in IU·mL^–1 (quantitative test result).

Statistical analysis
For comparison of qualitative QFT-GIT results of each individual before and after the TST, McNemar's test was used and a Wilcoxon signed rank test was performed to compare the strength of the IFN- response. Patient characteristics between QFT-GIT-positive and -negative individuals were compared using a Chi-squared or a Student's unpaired t-test as appropriate. A p-value <0.05 was considered statistically significant.

	RESULTS

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION ACKNOWLEDGEMENTS REFERENCES

 
Characteristics of study subjects and tuberculin skin test results
In all, 66 Dutch subjects were included (table 1). Fifteen healthy subjects were used as TST-negative controls. Out of a total of 46 TST-positive individuals, 23 had been exposed to a case of smear-positive pulmonary TB between 6 months and 1 yr before participating in the study (table 1). Of the remaining 23 TST-positive subjects (table 1), 10 had been exposed >3 yrs ago (median 4.5 yrs, range 3–53 yrs) and 13 had become TST positive >2 yrs ago and were found during routine screening because of a professionally related increased risk of exposure to TB patients. Five additional study subjects had been successfully treated for active TB 1.5–52 yrs before the study.

QFT-GIT before tuberculin skin testing
QFT-GIT was negative in all TST-negative controls (table 2). Out of the five cured TB patients, four had a strongly positive QFT-GIT results and in one subject, who had suffered TB 48 yrs earlier, the IFN- response was just below the cut-off level of the assay. QFT-GIT results were positive in 17 (37%) out of the 46 TST-positive individuals. Out of the 37 BCG-unvaccinated individuals, 15 (40.5%) had a positive test result. Among the 23 TST-positive individuals with recent exposure, 11 (48%) had a positive QFT-GIT result (median IFN- of 1.06 IU·mL^–1 among subjects with a positive test), while six out of 23 (26%) of TST-positive individuals with a more remote exposure had a positive test result (median IFN- of 0.76 IU·mL^–1 among positive responders; table 2). However, these differences were not statistically significant. In QFT-GIT-positive subjects, the mean interval between TST conversion and blood testing was shorter than in QFT-GIT-negative subjects (4.2 and 7.5 yrs, respectively) but this did not reach a level of significance.

Influence of tuberculin skin test on QFT-GIT
QFT-GIT was repeated at the time of reading of the TST (table 2). QFT-GIT results on days 0 and 3 are presented in figure 1. Due to logistical reasons, in two subjects (fig. 1) the blood sample for the second QFT-GIT was taken on days 10 and 11 after the TST. In the TST-negative group, QFT-GIT results remained negative. Overall, QFT-GIT results before and after TST were concordant in 95.5%. The percentage of individuals with test result that converted from negative to positive (two out of 45; 4.4%) was equal to those with a test result that changed from positive to negative (one out of 21; 4.8 %). If the analysis was restricted to those subjects who were re-evaluated precisely on day 3, these percentages were 2.3% (one out of 44) and 5.0% (one out of 20), respectively. Thus, no significant boosting of QFT-GIT results by TST was observed. Interestingly, in the two cases in which QFT-GIT converted from negative to positive, IFN- responses on day 0 were just below the cut-off of the assay. Latent infection with M. tuberculosis was likely in these subjects, one of whom was a Dutch BCG-unvaccinated individual with a TST of 25 mm observed during a contact investigation and the other was a Dutch, BCG-unvaccinated healthcare worker with a TST conversion. It is noteworthy that in the latter person, the blood sample for the second QFT-GIT was taken on day 10 after TST instead of on day 3. In a few M. tuberculosis-infected individuals, quantitative boosting of a positive IFN- response was seen following TST administration but responses remained at a similar level in most cases (fig. 1). No significant rise in IFN- responses between day 0 and day 3 could be observed in any of the study groups (table 2).

View larger version (12K): [in this window] [in a new window]   Fig. 1— Effect of tuberculin skin test (TST) on QuantiFERON®-TB Gold in-tube (QFT-GIT) response in a) controls, b) recent TST converters, c) remote TST converters and d) tuberculosis (TB) patients. QFT-GIT was carried out before TST administration (day 0) and 72 h later (day 3), at the time of reading of the TST in 15 TST-negative subjects, 23 TST-positive subjects with recent exposure to Mycobacterium tuberculosis, 23 TST-positive subjects with a more remote exposure and five cured TB patients. ------: The cut-off for a positive QFT-GIT response (interferon (IFN)- of 0.35 IU·mL–1). #: in two persons, a second QFT-GIT was done on day 10/11 instead of on day 3. In two subjects, QFT-GIT response was boosted from negative to positive (¶), and in one the opposite was seen ().

	DISCUSSION

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION ACKNOWLEDGEMENTS REFERENCES

To reach these conclusions, QFT-GIT was performed just before TST and on the day of reading of TST in 66 individuals, including TST-negative controls, TST-positive subjects with known exposure to TB and cured TB patients. Participants underwent a TST for the purpose of the present study only and sequential QFT-GIT samples were processed identically. However, the present study also has several possible limitations. First, the effect of TST on QFT-GIT was evaluated only 3 days after TST administration. From a two-step TST, it is known that maximal boosting of TST responses were found after an interval of 1–5 weeks 12, 13. Therefore, boosting of QFT-G(IT) after a longer interval cannot be excluded. In the two cases where QFT-GIT was repeated on days 10 and 11 after TST, a clear rise in IFN- response was observed; however, this could be caused by chance alone. In a recent study of 48 individuals, no boosting of the QFT-TB (based on PPD) was observed when the blood test was repeated 3 months after the TST 14. Although the present results are only applicable when the QFT-GIT is carried out on the day of TST reading, the information is very relevant, as this is the most practical moment to perform an IGRA when a two-step procedure (using a TST followed by an IGRA) is used for the screening of latent M. tuberculosis infection.

Secondly, the relatively small number of study individuals represents another possible limitation. However, individuals in whom boosting was most likely to occur were specifically selected. With repeated TST, the phenomenon of boosting is associated with a prior BCG vaccination, sensitisation to nontuberculous mycobacteria and remote M. tuberculosis infection 15–18. Since the peptides used in QFT-G(IT) are absent from BCG and from most environmental mycobacteria, except for Mycobacterium kansasii, Mycobacterium marinum and Mycobacterium szulgai 19, 20, a boosted QFT-G(IT) response, if present, would be most likely to be expected in the group with a remote infection. Therefore, a substantial number of individuals with well-defined remote M. tuberculosis infection was specifically included in the present study. These data show that there was no systematic change of QFT-GIT results 3 days after TST administration, also in the subgroup with remote M. tuberculosis infections. Similarly, no significant change in IFN- response was observed when evaluating quantitative QFT-GIT results. Only in a few cases did TST enhance pre-existing immune responses to M. tuberculosis-specific peptides, and it rarely caused a negative-to-positive change in QFT-G results. In the TST-negative control group, no rise in IFN- response was seen in any of the cases.

Previous studies indicated that M. tuberculosis-specific IGRAs, such as QFT-G and ELISPOT, are both specific and sensitive for the detection of latent M. tuberculosis infection 21–24. In the present study, however, only 37% of TST-positive subjects had a positive QFT-G result. This group consisted mainly of non-BCG-vaccinated individuals with a documented TST of 10 mm after exposure to a case of smear-positive pulmonary TB. In others, a TST conversion was observed during routine screening because of a professionally related increased risk of exposure to TB patients. Furthermore, data available from another study in the present authors' laboratory (S.M. Arend, Dept of Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands; personal communication) comparing short versus long incubation IGRAs showed that 22 out of 24 (92%) of the TST-positive study subjects had IFN- responses to M. tuberculosis-specific peptides of ESAT-6, CFP-10 and/or TB 7.7 in a 6-day cell culture. Since these antigens are highly specific for M. tuberculosis 25, also when tested in a 6-day cell culture 26–28, these data indicated that a latent M. tuberculosis infection was most likely in TST-positive subjects in the present study. Two other recent studies have also found a lower sensitivity of QFT-G than TST for detection of remote M. tuberculosis infection. In a recent study among jail inmates, more than half of the US-born TST-positive subjects were QFT-G negative 29. In a mostly BCG-vaccinated Korean control population, 51% was TST positive and only 4% was QFT-G positive, while the expected prevalence of M. tuberculosis infection was 33% 30. Thus, differences in sensitivity of QFT-G(IT) might be related to differences in study population, such as recent versus remote exposure, high- versus low-risk population, BCG background and prior treatment.

In conclusion, the present study demonstrated that systematic boosting of QuantiFERON-TB® Gold in-tube responses from negative to positive following tuberculin skin test administration does not occur and therefore shows that tuberculin skin test administration does not jeopardise the complete specificity of the assay. Thus, sequential use of tuberculin skin test for initial screening, followed by a QuantiFERON®-TB Gold (in-tube) on the day of tuberculin skin test reading is a reliable approach with which to screen for latent tuberculosis.

	ACKNOWLEDGEMENTS

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION ACKNOWLEDGEMENTS REFERENCES

 
The authors thank all volunteers who participated in this study, many of whom were employees of the KNCV Tuberculosis Foundation, The Hague, the Netherlands.

	REFERENCES

TOP ABSTRACT MATERIALS AND METHODS RESULTS DISCUSSION ACKNOWLEDGEMENTS REFERENCES

 

1. Pai M, Riley LW, Colford JM Jr. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004;4:761–776.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
2. Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet 2000;356:1099–1104.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
3. Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 2004;170:59–64.[Abstract/Free Full Text]
4. Ravn P, Munk ME, Andersen AB, et al. Prospective evaluation of a whole-blood test using Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10 for diagnosis of active tuberculosis. Clin Diagn Lab Immunol 2005;12:491–496.[CrossRef][Medline] [Order article via Infotrieve]
5. Brock I, Weldingh K, Lillebaek T, Follmann F, Andersen P. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 2004;170:65–69.[Abstract/Free Full Text]
6. Brock I, Weldingh K, Leyten EM, Arend SM, Ravn P, Andersen P. Specific T-cell epitopes for immunoassay-based diagnosis of Mycobacterium tuberculosis infection. J Clin Microbiol 2004;42:2379–2387.[Abstract/Free Full Text]
7. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974;99:131–138.[Abstract/Free Full Text]
8. Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis 1979;119:827–830.[Web of Science][Medline] [Order article via Infotrieve]
9. Comstock GW, Ferebee SH, Hammes LM. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis 1967;95:935–943.[Web of Science][Medline] [Order article via Infotrieve]
10. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc 1970;26:28–106.[Medline] [Order article via Infotrieve]
11. Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 1999;159:15–21.[Free Full Text]
12. Cauthen GM, Snider DE Jr, Onorato IM. Boosting of tuberculin sensitivity among Southeast Asian refugees. Am J Respir Crit Care Med 1994;149:1597–1600.[Abstract]
13. Thompson NJ, Glassroth JL, Snider DE Jr, Farer LS. The booster phenomenon in serial tuberculin testing. Am Rev Respir Dis 1979;119:587–597.[Web of Science][Medline] [Order article via Infotrieve]
14. Nguyen M, Perry S, Parsonnet J. QuantiFERON-TB predicts tuberculin skin test boosting in U.S. foreign-born. Int J Tuberc Lung Dis 2005;9:985–991.[Web of Science][Medline] [Order article via Infotrieve]
15. Menzies R, Vissandjee B, Rocher I, St Germain Y. The booster effect in two-step tuberculin testing among young adults in Montreal. Ann Intern Med 1994;120:190–198.[Abstract/Free Full Text]
16. Richards NM, Nelson KE, Batt MD, Hackbarth D, Heidenreich JG. Tuberculin test conversion during repeated skin testing, associated with sensitivity to nontuberculous mycobacteria. Am Rev Respir Dis 1979;120:59–65.[Web of Science][Medline] [Order article via Infotrieve]
17. Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 1999;159:15–21.[Free Full Text]
18. Thompson NJ, Glassroth JL, Snider DE Jr, Farer LS. The booster phenomenon in serial tuberculin testing. Am Rev Respir Dis 1979;119:587–597.[Web of Science][Medline] [Order article via Infotrieve]
19. Arend SM, de Haas P, Leyten E, et al. ESAT-6 and CFP-10 in clinical versus environmental isolates of Mycobacterium kansasii. J Infect Dis 2005;191:1301–1310.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
20. Arend SM, van Meijgaarden KE, de Boer K, et al. Tuberculin skin testing and in vitro T cell responses to ESAT-6 and culture filtrate protein 10 after infection with Mycobacterium marinum or M. kansasii. J Infect Dis 2002;186:1797–1807.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
21. Shams H, Weis SE, Klucar P, et al. Enzyme-linked immunospot and tuberculin skin testing to detect latent tuberculosis infection. Am J Respir Crit Care Med 2005;172:1161–1168.[Abstract/Free Full Text]
22. Ewer K, Deeks J, Alvarez L, et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 2003;361:1168–1173.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
23. Lalvani A, Pathan AA, Durkan H, et al. Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 2001;357:2017–2021.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
24. Brock I, Weldingh K, Lillebaek T, Follmann F, Andersen P. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 2004;170:65–69.[Abstract/Free Full Text]
25. Pai M, Riley LW, Colford JM Jr. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004;4:761–776.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
26. Ravn P, Demissie A, Eguale T, et al. Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. J Infect Dis 1999;179:637–645.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
27. Munk ME, Arend SM, Brock I, Ottenhoff TH, Andersen P. Use of ESAT-6 and CFP-10 antigens for diagnosis of extrapulmonary tuberculosis. J Infect Dis 2001;183:175–176.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
28. Arend SM, Andersen P, van Meijgaarden KE, et al. Detection of active tuberculosis infection by T cell responses to early-secreted antigenic target 6-kDa protein and culture filtrate protein 10. J Infect Dis 2000;181:1850–1854.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
29. Porsa E, Cheng L, Seale MM, et al. Comparison of a new ESAT-6/CFP-10 peptide-based gamma interferon assay and a tuberculin skin test for tuberculosis screening in a moderate-risk population. Clin Vaccine Immunol 2006;13:53–58.[Abstract/Free Full Text]
30. Kang YA, Lee HW, Yoon HI, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 2005;293:2756–2761.[Abstract/Free Full Text]

This article has been cited by other articles:

				L. Richeldi Diagnosing Latent Tuberculosis Infection: Guess Who's Coming to Dinner? Am. J. Respir. Crit. Care Med., July 1, 2009; 180(1): 1 - 2. [Full Text] [PDF]

				R. N. van Zyl-Smit, M. Pai, K. Peprah, R. Meldau, J. Kieck, J. Juritz, M. Badri, A. Zumla, L. A. Sechi, E. D. Bateman, et al. Within-Subject Variability and Boosting of T-Cell Interferon-{gamma} Responses after Tuberculin Skin Testing Am. J. Respir. Crit. Care Med., July 1, 2009; 180(1): 49 - 58. [Abstract] [Full Text] [PDF]

				Interferon-gamma release assays and TB diagnosis DTB, June 1, 2009; 47(6): 67 - 70. [Abstract] [Full Text] [PDF]

				C. A. Baker, W. Thomas, W. M. Stauffer, P. K. Peterson, and D. T. Tsukayama Serial Testing of Refugees for Latent Tuberculosis Using the QuantiFERON-Gold In-Tube: Effects of an Antecedent Tuberculin Skin Test Am J Trop Med Hyg, April 1, 2009; 80(4): 628 - 633. [Abstract] [Full Text] [PDF]

				L. Richeldi, B. M. Bergamini, and F. Vaienti Prior tuberculin skin testing does not boost QuantiFERON-TB results in paediatric contacts Eur. Respir. J., August 1, 2008; 32(2): 524 - 525. [Full Text] [PDF]

				J. C. Choi, J. W. Shin, J. Y. Kim, I. W. Park, B. W. Choi, and M.-K. Lee The Effect of Previous Tuberculin Skin Test on the Follow-up Examination of Whole-Blood Interferon-{gamma} Assay in the Screening for Latent Tuberculosis Infection Chest, June 1, 2008; 133(6): 1415 - 1420. [Abstract] [Full Text] [PDF]

				S. Perry, L. Sanchez, S. Yang, Z. Agarwal, P. Hurst, and J. Parsonnet Reproducibility of QuantiFERON-TB Gold In-Tube Assay Clin. Vaccine Immunol., March 1, 2008; 15(3): 425 - 432. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 29/6/1212    most recent 09031936.00117506v1 Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (16) Citing Articles via Google Scholar Google Scholar Articles by Leyten, E. M. S. Articles by Arend, S. M. Search for Related Content PubMed PubMed Citation Articles by Leyten, E. M. S. Articles by Arend, S. M.